Oppenheimer analyst Ittai Kidron raised his price target for Alteryx to $120 from $93 after coming away from the company's Inspire conference incrementally positive on the demand environment, strategic direction, growing platform value, growing ecosystem and ability to sustain strong net expansion rates above 130%. His survey of 20 customers showed steady year over year expectations for spending increases, while his conversations reinforced that analytics is growing in importance to daily business processes and Alteryx has a differentiated position that saves customers time. The analyst reiterates an Outperform rating on the shares.

New option listings for April 23rd include Express Inc (EXPRQ). Option delistings effective April 23rd include PGT Innovations Inc (PGTI), NGM Biopharmaceuticals Inc (NGM), Karuna Therapeutics Inc (KRTX), KINNATE BIOPHARMA INC (KNTE), Daseke Inc (DSKE), Tritium Dcfc Ltd (DCFC), Xtrackers MSCI All China Equity ETF (CN), CymaBay Therapeutics Inc (CBAY), Alteryx Inc (AYX), XTRACKERS MSCI CHINA A INCLUSION EQUITY ETF (ASHX), Recro Pharma, Inc. (SCTL), Splunk Inc (SPLK), and Textainer Group Holdings Limited (TGH).